Quick Answer
OCULAR THERAPEUTIX, INC reported Net Income Loss of -$265.94 million for the year ending 2025.
- OCULAR THERAPEUTIX, INC showed a decrease of -37.4% in Net Income Loss from 2024 to 2025.
- This data is from OCULAR THERAPEUTIX, INC's annual report (Form 10-K), filed with the SEC on February 5, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: -$11.52 million | Q4 2015: -$10.64 million | Q1 2016: -$10.84 million | Q2 2016: -$11.45 million | Q3 2016: -$9.60 million | Q4 2016: -$12.82 million | Q1 2017: -$16.02 million | Q2 2017: -$18.69 million | Q3 2017: -$15.57 million | Q4 2017: -$13.10 million | Q1 2018: -$13.77 million | Q2 2018: -$13.80 million | Q3 2018: -$15.01 million | Q4 2018: -$17.40 million | Q1 2019: -$17.12 million | Q2 2019: -$24.45 million | Q3 2019: -$18.78 million | Q4 2019: -$26.02 million | Q1 2020: -$21.51 million | Q2 2020: -$36.57 million | Q3 2020: -$11.94 million | Q1 2021: $3.12 million | Q2 2021: -$8.48 million | Q3 2021: $2.66 million | Q1 2022: -$12.54 million | Q2 2022: -$18.77 million | Q3 2022: -$24.19 million | Q1 2023: -$30.32 million | Q2 2023: -$20.68 million | Q3 2023: -$516.0 thousand | Q1 2024: -$64.85 million | Q2 2024: -$43.78 million | Q3 2024: -$36.49 million | Q1 2025: -$64.05 million | Q2 2025: -$67.81 million | Q3 2025: -$69.42 million.
- Over the full 14 years of available data (2012 to 2025), OCULAR THERAPEUTIX, INC's Net Income Loss has declined by 1,787.0%.
- Historical annual values: Fiscal year 2025: -$265.94 million | Fiscal year 2024: -$193.51 million | Fiscal year 2023: -$80.74 million | Fiscal year 2022: -$71.04 million | Fiscal year 2021: -$6.55 million | Fiscal year 2020: -$155.64 million | Fiscal year 2019: -$86.37 million | Fiscal year 2018: -$59.98 million | Fiscal year 2017: -$63.39 million | Fiscal year 2016: -$44.70 million | Fiscal year 2015: -$39.75 million | Fiscal year 2014: -$28.65 million | Fiscal year 2013: -$13.32 million | Fiscal year 2012: -$14.09 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: